Paragon ID (Euronext Paris - FR0011980077 - PID), champion européen des solutions d’identification dédiées aux marchés de l’e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques, annonce avoir signé auprès de Transport for London, organisme public en charge des transports en commun de la ville de Londres et du Grand Londres (Royaume-Uni), une commande de 2,2 M£ (environ 2,5 M€) pour la fabrication des cartes de transport Oyster tout au long de l’année 2018.
Les cartes Oyster sont des cartes à puce sans-contact, chargées avec des crédits, qui permettent de voyager en métro, en bus, sur les lignes DLR et London Overground (métro aérien), en tramway, avec la compagnie de transports fluviaux MBNA Thames Clippers, et dans la plupart des trains de la National Rail circulant dans Londres. Des millions de trajets sont effectués quotidiennement en utilisant la carte Oyster1 , ce qui en fait l'une des options les plus appréciées par tous ceux qui souhaitent accéder aux transports en commun de la capitale britannique.
Paragon ID est l'une des rares sociétés accréditée ITSO (Integrated Transport Smartcard Organisation), le standard national britannique de Smart Ticketing (billetterie intelligente), et dispose d’usines de fabrication au Royaume-Uni et en Europe.
Le groupe offre une gamme complète de solutions (tickets, magnétiques, tickets sans-contact, cartes sans-contact, services sécurisés, terminaux, applications mobiles, etc.) pour le secteur du transport public, garantissant la sécurité et la fluidité des contrôles d’accès dans des centaines de villes. Paragon ID accompagne ainsi les opérateurs de transport dans le cadre de leur migration progressive du ticket traditionnel, à base de papier, vers des solutions de type Smart Ticket (ticket RFID), Smart Card ou des solutions de billettique embarquée dans un smartphone (type HCE).
Julien Zuccarelli, Directeur général de Paragon ID, déclare :
« Nous sommes très heureux de poursuivre notre relation avec Transport for London et de les compter parmi notre liste croissante de clients dans le secteur des transports en commun. Par ce succès, nous réaffirmons notre position de leader et notre crédibilité sur le marché de la billetterie iintelligente, dont les cartes Oyster constituent l'un des meilleurs exemples technologiques. »
1 Nombre de cartes Oyster utilisées quotidiennement pour voyager : http://content.tfl.gov.uk/daily-breakdown-of-oyster-cardusage-data.pdf
A propos de Paragon ID Issu du rapprochement, fin avril 2017, entre ASK et la division Identification & Traçabilité de Paragon Group Ltd., Paragon ID est un champion des solutions d’identification dédiées aux marchés de l’e.ID, du Transport & Smart Cities, et de la Traçabilité & Protection des marques.
Paragon ID offre une large gamme de solutions, embarquées dans tous les types de supports (Passeports, Documents d'identité, Tickets & Etiquettes intelligentes, Smart Cards, Smartphones, Cartes bancaires).
S’appuyant sur plus de 600 collaborateurs à travers le monde, Paragon ID dispose d’une base industrielle forte, avec des usines à proximité de ses clients mondiaux.
Paragon ID est côté sur Euronext Paris. Libellé : Paragon ID - Code ISIN : FR0011980077 - Code mnémonique : PID. Plus d’informations sur Paragon-id.com
Paragon ID ACTUS finance & communication ACTUS finance & communication
Directeur Général Relation investisseurs Relation presse
Julien Zuccarelli Mathieu Omnes Jean-Michel Marmillon
Tél.: +33 (0)4 97 21 48 56 Tél. : +33 (0)1 53 67 36 92 Tél. : +33 (0)1 53 67 36 73
• Creating a turnkey solution for operators and TV broadcasters, covering encoding, transcoding, packaging and storage;
• Expanding in the video encoding market;
• Benefiting from a whole raft of identified operating synergies;
• Acquisition wholly paid for in new ANEVIA shares.
Anevia, a leading provider in OTT and IPTV software solutions, has announced an agreement to acquire 100% of the share capital in French company, Keepixo.
Keepixo is a spin-off of Grenoble-based video coding expert, Allegro DVT, specialising in the development of video compression software for TV operators, to enable live or near-live broadcasts for multi-screen TV. Keepixo’s solutions have been sold to more than 150 clients worldwide, including 40 Tier-1 operators. In 2017, Keepixo recorded sales of €0.9m and had 14 employees, most of whom based in Grenoble.
The acquisition will enable Anevia to offer operators and broadcasters a new, end-to-end encoding, transcoding, storage and packaging solution that will notably comply with new quality standards, such as 4K and HDR.
A whole raft of potential synergies has now been identified as a result of this tie-up, notably including:
• An enhanced product portfolio, adding video compression software to the existing catalogue, with a view to providing a turnkey solution;
• Larger teams, with the addition of 14 new employees, of which 10 engineers sharing a similar software architecture design and company culture to those of Anevia;
• Increased market potential, with: - A comprehensive and competitive solution with which to address the Tier-2 and Tier-3 operators market, in which cost concerns take precedence over so-called ‘Best of Breed’ technologies; - The development of a transcoding solution for local network headends for the enterprises market;
• Combined technological expertise, allowing the two companies to:
- Share technical skills, notably in packaging and low latency broadcasting technologies;
- Pooling Keepixo’s expertise in audio/video compression (HEVC, 4K and HDR) and low latency packaging with that of Anevia in network architecture and video solution integration;
- Sharing Quality Assurance methods and processes; - Combining R&D resources;
- Sharing project and support/operations-related resources.
The acquisition is to be fully funded via an exchange of shares, in which new Anevia shares will be issued and exchanged for Keepixo shares under an in-kind contribution agreement.
Notes to Editors:
TERMS OF THE TRANSACTION
Anevia’s Executive Board having approved the transaction, a Contribution and Exchange Agreement was subsequently signed between Anevia and Keepixo shareholders. Serge Godard was appointed shares auditor and tasked with writing a report on the value of the in-kind contribution and on the remuneration of the shares contributed (and on the equitable nature of the exchange ratio).
Under the Contribution and Exchange agreement, the in-kind contribution from Keepixo is to be remunerated via the issuance of 307,200 new Anevia shares at a unit price of €2.63**, consisting of a par value of €0.05 and a contribution premium of €2.58 per unit, thereby valuing Keepixo at €807,936.
Final completion of the transaction will be subject to the removal of all the usual conditions precedent and to the shareholders’ vote at the Extraordinary General Meeting, which has been convened, on first notice, on April 12, 2018.
The new shares will be subject to a request for admission to trading on the Euronext Growth market in Paris, under the same ticker as existing Anevia shares. Subject to the AGM’s approval of the in-kind contribution, and as a result of the transaction, Anevia’s share capital will come to €192,979.60 divided into 3,859,592 shares. The 307,200 new Anevia shares will therefore account for 7.96% of Anevia’s share capital and 5.77% of its voting rights.
Provisional acquisition timetable
Notice of the meeting published in BALO (French Mandatory Legal Notices Bulletin) 3/7/2018
Convening notice of EGM 3/26/2018
Extraordinary General Meeting 4/12/2018
Settlement and delivery of new shares 4/16/2018
** This figure equates to the average price of Anevia shares over the 20 trading sessions prior to December 4, 2017, the date on which the parties decided on the acquisition price.
Impact on current shareholders’ equity
The issuance of 307,200 new Anevia shares would have the following impact on shareholders owning 1%, 5% and 10% of the Company’s share capital prior to the agreement (calculation based on the number of shares comprising the company’s share capital on the date of this press release):
Share of equity (%)
Prior to the issue of 307,200 new shares ............................10 % 5 % 1 %
Subsequent to the issue of 307,200 new shares ................. 9.20 % 4.60 % 0.92 %
Anevia is a leading OTT and IPTV software vendor that specialises in delivering innovative solutions for live TV, near-live, video on demand (VOD) and multi-screen. Anevia was founded in 2003 by the developers of the well-known VLC media player, and since then the company has pioneered unique solutions across several fields, including cloud DVR and multi-screen. Anevia’s mission is to deliver innovative technologies that enable viewers to enjoy a next-generation TV experience – wherever, whenever and on every screen. Anevia’s solutions have been adopted by globally-renowned TV broadcasters, telecommunication and pay-TV operators, video service providers and many private and public companies. Anevia is headquartered in France, with regional offices in the USA and Dubai. Anevia is listed on the Paris Euronext Growth market. For more information please visit www.anevia.com.
Video compression expert Keepixo develops and sells software solutions for distributing audiovisual content in IPTV and OTT (over-the-top) mode. Keepixo’s solutions enable video compression and the conversion of audio/video data into the formats and protocols required for Internet routing in IPTV and OTT TV mode (OTT packaging). Keepixo offers a broad range of products, including video encoders and transcoders for live and VOD broadcasting, mosaic TV channel generators and live-to-VOD recording solutions for catch-up TV services. For more information please visit www.keepixo.com.
Sabine de Leissègues Alexandre Commerot
Marketing & Communications Director Isabelle Dray (press relations)
Tel: +33 1 81 94 50 95 Tel: +33 1 56 88 11 11
ISIN Code: FR0011910652
Ticker symbol: ALANV
Number of shares comprising the share capital: 3,551,218
This press release contains non-factual information including, notably but not exclusively, some forward-looking statements about future results and other planned events. These statements are based on the current outlook taken, and assumptions made, by the Company’s management. These take into account both known and unknown risks and uncertainties that could potentially lead to significant differences in terms of earnings, profitability and planned events. Furthermore, the accuracy of the statistics and provisional information provided by, or derived from, industry publications or third party sources and contained in this press release has neither been verified, nor is the subject of any announcements or guarantees made, by Anevia or its shareholders and affiliates, directors, executives and advisors, or employees: such provisional statistics and information are included in this press release for information purposes only. Finally, the present press release may be drafted in French and English. In the event of discrepancies between the two publications, the French-language version shall take precedence.
Smartphones are increasingly delivering verified treatments for diabetes, addictions and ADHD
LUANN STOTTLEMYER has had diabetes for 23 years, but it was only in 2016 that her doctor prescribed a treatment that changed her life. It has allowed her to bring her blood-sugar levels under control and lose weight. Yet this miracle of modern science is not a new pill. It is a smartphone app called BlueStar.
The program is one of a growing number of apps that America’s Food and Drug Administration (FDA) has approved to treat everything from diabetes to substance abuse. The FDA has encouraged firms to join a scheme that aims to streamline the regulatory process for such treatments. There are many candidates: at least 150 firms globally are developing some form of “digital therapeutic” (“digiceutical” in the lingo), says Mark Sluijs, who advises Merck, a big American drugmaker.
Unlike other sorts of digital health apps, digiceuticals have been tested for efficacy, approved by regulatory agencies such as the FDA and are prescribed by a doctor. Most gather data, either by asking patients for information or by using sensors, and provide real-time guidance. Diabetes apps, for instance, work with connected monitors and use the information to manage symptoms. Apps that help users to stop smoking combine a breath sensor with coaching on how to quit. Addiction-fighting apps can be based on cognitive behavioural therapy.
Most apps are developed by startups, many of which are based in and around Boston. One such, Pear Therapeutics, has a pipeline of treatments at various stages of development, much like a conventional pharmaceutical firm. These apps are aimed at treating a range of conditions: opioid addiction, schizophrenia, anxiety, insomnia, post-traumatic stress disorder (PTSD), depression and chronic pain. Pear’s reSET app, for instance, which treats disorders involving the misuse of alcohol, cocaine and other stimulants, has been approved for sale and should be on the market in early 2018. The app will be more effective than conventional treatments, claims Corey McCann, Pear’s chief executive. It carefully trains patients to recognise daily triggers and cravings and to monitor and track these with their doctor.
Another area of attention is medication for attention-deficit hyperactivity disorder (ADHD), on which Americans spend $14bn annually. Akili Interactive, another startup, recently completed a trial showing that a computer game it has developed to treat ADHD can improve attention and inhibitory control in children. If approved, the game would be the first digital therapeutic for this disease. As well as competing with existing drugs, it may also appeal to parents who are reluctant to medicate their children for ADHD.
Some digiceuticals will work better alongside conventional drugs, rather than on their own—opening up possibilities for alliances between tech and pharma firms. Voluntis, a startup, develops companion software for specific medications or medical devices. These programs can monitor side-effects, help manage symptoms and connect patients with doctors and nurses.
Pharma firms and venture capitalists remain cautious, however. Only a few drugmakers have invested in startups, and VCs are waiting to see what happens with the current crop of businesses, says Nikhil Krishnan of CB Insights, a data provider. One reason for the reluctance is a lack of rules for prescribing and paying for these apps—a problem that a new lobbying group, the Digital Therapeutics Alliance, wants to tackle. Cultural hurdles have to be overcome, too: many patients will find it hard to believe that software can be as effective as a pill. Analysts estimate that the market for digiceuticals will be worth a modest $9bn by 2025.
Once accepted, however, digiceuticals should take off and may well be created by large pharma and tech firms as well. The apps make it possible both to measure whether patients are adhering to their treatment, and to collect evidence on outcomes. Barriers to entry for startups are lower than for drugmakers, which need access to costly laboratories and manufacturing facilities. So many apps will compete to treat the same disease, which should spark very rapid innovation—a rare phenomenon in medicine—and perhaps even to lower prices, a rarer one still.
Clinical Evaluators Share Positive Results of Revolutionary Technology that Combines the Precision of Robotic-Assisted Bone Cutting with Dynamic Real-Time Soft Tissue Management
(Raynham, MA February 5, 2018) OMNIlife science™, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their breakthrough OMNIBotics Active Spacer technology were featured at the International Congress for Joint Reconstruction (ICJR) 10th Annual Hip & Knee Conference held in Vail, CO from January 18-21.
The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. The more than 150 attendees learned about OMNIBotics Active Spacer technology in both a pre-recorded surgery presentation and a podium presentation. The surgery, “TKA Utilizing OMNIBotics Active Spacer Robotically Assisted Ligament Balancing System” was performed and narrated by Jeffrey H. DeClaire, MD, DeClaire LaMacchia Orthopaedic Institute, Rochester Hills, MI. The podium presentation “Ligament Balancing Technology in TKA” was given by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT.
Dr. DeClaire commented, “With this new technology and the ability to capture accurate data, the Active Spacer can help to more accurately and consistently restore the normal soft tissue balance of the knee with the potential to improve patient outcomes and patient satisfaction.”
The OMNIBotics Active Spacer, with more than 150 procedures performed to date, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. Since sub-optimal soft tissue balancing is a potential contributing factor to patient dissatisfaction with their knee replacement, OMNI developed this device to address that need. When the OMNIBotics Active Spacer is combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.
“The Active Spacer provides the most accurate and useful information to date for achieving good balance in knee replacement patients,” stated Dr. Keggi. “Surgeons can now see the full motion and precise balance of the knee in real time, which provides important feedback to optimize the function of the knee.”
he OMNIBotics Active Spacer received FDA clearance in early September, 2017 and is currently in clinical evaluation at six sites in the United States and one in Australia.
OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward‐looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward‐looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release
Cindy Holloway, Director of Marketing Communications
Phone: (508) 824‐2444
PARIS, le 15 janvier 2018 - EKINOPS (Euronext Paris - FR0011466069 – EKI), fournisseur leader de solutions de télécommunications dédiées aux opérateurs de télécommunications, publie son chiffre d’affaires consolidé au titre de l’exercice 2017, clos le 31 décembre 2017. La société OneAccess est consolidée par intégration globale depuis le 1er octobre 2017 dans les comptes du groupe.
En M€ - Données consolidées non auditées 2017 2018 Variation
Chiffres d’affaires 34,31 18,18 +89%
Sur l’exercice 2017, le chiffre d’affaires consolidé d’Ekinops s’est établi à 34,31 M€, en croissance de +89%. « Nous sommes très fiers d’avoir pu intégrer l’équipe talentueuse de OneAccess au 4ème trimestre et l’accueil de ce rapprochement par nos clients opérateurs est excellent » commente Didier Brédy, Président-Directeur général d’Ekinops. « Nous nous sommes réorganisés pour être en mesure de livrer de la croissance en tirant parti de nos solutions innovantes et de notre portefeuille clients riche en opérateurs de rang 1.
Une année 2017 marquée par des succès stratégiques, commerciaux et technologiques
L’année 2017 marque un véritable changement de dimension pour le groupe à travers le rapprochement stratégique avec OneAccess. Cette opération a permis de donner naissance à un acteur de référence des solutions pour les réseaux télécom, présent à la fois sur les solutions de transport optique, les services Ethernet et de routage d’entreprise.
La vision technologique commune des deux sociétés, avec une forte culture logicielle, et leur très grande complémentarité produits, allant de la couche transport des réseaux (couche 1) aux besoins en matière de routage et de services Ethernet et IP (couches 2 et 3), vont permettre au groupe désormais constitué de pénétrer de nouveaux segments de marché et de générer de la croissance dans un marché où le trafic Internet ne cesse d’augmenter et les besoins des opérateurs sont croissants.
En matière de transport optique, l’année 2017 a été marquée par le succès commercial des solutions 100G & 200G et la mise sur le marché, en fin d’année, d’un nouveau module optique 100G / 200G de nouvelle génération, doté d’une taille réduite, permettant de diviser par deux la consommation électrique et de diminuer sensiblement le coût du transport des données sur les réseaux optiques.
En matière de routage et de virtualisation des réseaux, le lancement du nouveau système d'exploitation OneOS6 constitue la principale évolution technologique de l’année écoulée. OneOS6 offre aux opérateurs la possibilité de prendre le contrôle de leur migration vers des services virtualisés à l'aide de solutions complètes, flexibles et totalement indépendantes des fournisseurs d’équipements.
Activité de la filiale OneAccess
Le groupe a bénéficié de la consolidation de la société OneAccess à compter du 4ème trimestre 2017, à hauteur de 15,24 M€ sur la période. Sur l’exercice 2017, la zone EMEA (Europe, Moyen-Orient & Afrique) a représenté 86% de l’activité de la nouvelle filiale, la région APAC (Asie-Pacifique) 10% et les Amériques 4%.
Sur le plan commercial, OneAccess compte cinq opérateurs de rang 1 (Tier 1) au sein de son Top 10 clients 2017.
Activité du périmètre historique d’Ekinops
Sur le périmètre historique d’Ekinops (hors OneAccess), la croissance annuelle s’est établie à +5% par rapport à 2016 (+6% à taux de change constants).
Le ralentissement de la croissance au 4ème trimestre est la conséquence du décalage du cycle d’investissement du 1er client d’Ekinops en 2016. Hors impact de ce décalage de commandes avec ce client basé dans la zone EMEA Nord, la croissance annuelle d’Ekinops s’est établie à +14% en 2017.
La croissance annuelle a été portée par la progression des ventes de solutions 100G & 200G, en hausse de +18% sur l’ensemble de l’exercice. Cette ligne business a représenté 71% de l’activité en 2017 (vs. 61% en 2016). Les activités de services ont pour leur part progressé de +14% sur l’année (représentant 11% du chiffre d’affaires total). Enfin, les ventes d’équipements 10G ont poursuivi leur recul programmé (-30%), et ne représentaient plus désormais que 18% de l’activité (vs. 26% en 2016).
Sur le plan géographique, les Etats-Unis sont demeurés la 1ère zone de facturation d’Ekinops en 2017, représentant 40% du chiffre d’affaires, poids stable par rapport à 2016. Avec 31% des facturations totale (38% en 2016), EMEA Nord est restée la 2ème zone géographique en 2017 malgré l’impact du décalage de commandes sur 2018 du 1er client. L’Europe de l’Est a enregistré une activité dynamique, totalisant 23% de l’activité de l’année (vs. 12% en 2016). Enfin, EMEA Sud a représenté 6% des facturations en 2017, contre 10% un an plus tôt.
Agenda financier 2018
Ekinops annonce son agenda de publications financières au titre de l’exercice 2018. Toutes les publications interviendront après la clôture du marché d’Euronext Paris.
A propos d’EKINOPS
Ekinops est un fournisseur leader de solutions de télécommunications, ouvertes et interopérables, destinées aux fournisseurs de services (opérateurs de télécommunications et entreprises) à travers le monde.
Les solutions Ekinops, hautement programmables et évolutives, permettent le déploiement rapide et de manière flexible de nouveaux services de transport optique, haut débit et haute vitesse, ainsi que des services d'entreprise, notamment à travers la virtualisation des réseaux. Le portefeuille de solutions se compose de deux ensembles de produits parfaitement complémentaires :
▪ la plateforme Ekinops 360, afin de répondre aux besoins des réseaux métropolitains, régionaux et longue distance, à partir d’une architecture simple et très intégrée, pour la couche 1 (transport) des réseaux ;
▪ les solutions OneAccess, afin de proposer un large choix d'options de déploiement, physiques et virtualisées, pour les couches 2 et 3 (liaison et réseau).
À mesure que les fournisseurs de services adoptent les modèles de déploiement SDN (Software Defined Networking) et NFV (Network Functions Virtualization), les solutions Ekinops leur permettent ainsi de migrer, de manière transparente, vers des architectures ouvertes et virtualisées.
Ekinops dispose d’une organisation mondiale qui lui permet d’opérer sur les 4 continents. Ekinops est coté sur Euronext à Paris.
Libellé : Ekinops
Code ISIN : FR0011466069
Code mnémonique : EKI
Nombre d’actions composant le capital social : 21 242 747
Plus d’informations sur www.ekinops.net
Tél. : +33 (0)1 53 67 36 92
Tél: +33 (0)1 77 71 13 20
Tél. : +33 (0)1 53 67 36 74
Cambridge, MA, and Columbia, MD, 09 january 2018
Voluntis and WellDoc®, two of the industry’s leading digital therapeutics companies, announced today a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans.
Voluntis developed Insulia®, an FDA-cleared, prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations for people with type 2 diabetes while enabling the health care team to remotely monitor progress.
The developer of BlueStar® – an FDA-cleared, digital therapeutic for individuals with type 2 diabetes – WellDoc is the first digital health company in the US to conduct randomized clinical trials that demonstrate significant clinical outcomes, as published in multiple peerreviewed journals and presented at leading industry conferences. The clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for individuals living with type 2 diabetes who used BlueStar1. BlueStar provides real-time and timely individualized coaching and support, as well as educational tools that are actionable and personal for individuals living with type 2 diabetes.
“We are excited to be working with WellDoc so that we can bring together extensive coaching and actionable insulin titration recommendations,” said Voluntis Chief Executive Officer Pierre Leurent. “By bringing both products and these capabilities under the same umbrella, we hope to further simplify treatment for people living with type 2 diabetes.”
The pioneering companies maintain a shared vision of how digital technologies can positively impact the health of patients. In order to realize this goal, Voluntis and WellDoc are committed to clinical validation of their solutions, rigorous adherence to regulatory requirements, working with stakeholders to drive utilization and reimbursement, and collaboration with industry partners that complement each company’s respective solutions.
“We are pleased to announce this significant commercial agreement with Voluntis and believe that our two organizations greatly complement each other,” said WellDoc President and CEO Kevin McRaith. “Together, we will be able to provide a combined solution that providers, health systems, and health plans can offer to their members with type 2 diabetes.”
Efforts are already underway to implement a combined product offering, which will be rolled out through a phased approach. The companies expect to begin joint discussions with stakeholders (i.e., health systems and health plans) as early as late-Q1 2018 to convey the advantages and value of the combined product offering as enabled by the Voluntis-WellDoc commercial agreement.
WellDoc® is a leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes.
Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. For more information, visit www.welldoc.com.
Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance. For more information, visit http://www.voluntis.com/.
Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress. A healthcare practitioner prescribes Insulia using their dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs. The user then receives an activation code to get started with their personalized app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time. These are constantly updated using clinical algorithms built into the application. Data is automatically shared with the health care team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. This enables providers to deliver tailored telemedicine services, a practice increasingly supported by payers worldwide. Insulia is available for people using any brand of basal insulin including Lantus®, Levemir®, Toujeo®, Tresiba® (U-100) and Basaglar®. For more information, visit http://www.insulia.com.
Media Contact for WellDoc:
PressComm PR for WellDoc
 Quinn CC, et al. Diabetes TechnolTher.2008 ;10(3) :160-168. Quinn CC, et al. Diabetes Care. 2011: 34(9): 1934-1942.
Richard Katz, MD; George Washington University Medical Center; Journal of Health Communication, December 2011.
Quinn, CC, et al. Glycemic Control: Impact on Physician Prescribing Behavior, Presentation ADA 72ndScientific Sessions, 2012.
Tang PY, et al. "eHealth-Assisted Lay Health Coaching for Diabetes Self-Management Support." American Diabetes Association 76th Scientific Sessions Poster Presentation 2016 presented at AADE San Diego 2016.
+33 1 80 03 19 52
Schlieren (Zurich), Switzerland, January 8, 2018 – Kuros Biosciences (SIX: KURN) announced today that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) access to Kuros’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to
The amendment extends the field from oncology to all indications and broadens the range of product candidates covered. In exchange for the amendment of the license, Kuros receives an upfront payment
“We are excited about the amendment of the existing agreement with Checkmate and continue to believe that Checkmate is well positioned to advance treatment options for patients”, commented Joost de Bruijn, CEO of Kuros. “The Checkmate team is pleased to obtain these rights to Kuros’ VLP platform, which we believe has a great deal of potential for further clinical development”, affirmed Art Krieg, CEO of Checkmate.
For further information, please contact:
Joost de Bruijn
Chief Executive Officer
Tel +31 6 21 21 76 03
About Kuros Biosciences AG
Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.